Insilico Medicine Inks $2.75B Lilly Deal for AI Oral Drug Candidates

Insilico Medicine, a clinical-stage AI-driven biotech, entered a partnership with Eli Lilly granting the pharma giant exclusive worldwide rights to develop, manufacture, and commercialize select preclinical oral drug candidates discovered via Insilico's Pharma.AI platform. The deal provides Insilico with $115 million upfront and potential milestone payments reaching $2.75 billion tied to regulatory approvals and commercial achievements across multiple R&D programs focused on Lilly-chosen targets. Specific assets remain undisclosed, though Insilico's pipeline notes an out-licensed GLP-1 targeting candidate, aligning with reports of a diabetes-focused agonist.

This agreement builds on Insilico's expanding collaboration network, which generated $1.3 billion in new deals during 2025 and early 2026, elevating cumulative partnership value to $4.6 billion with firms like Servier, Hisun Pharma, and others. Following its December 2025 Hong Kong IPO that raised significant capital to $393.3 million in cash reserves, Insilico advances its dual-engine model of AI platform enhancement and proprietary pipeline growth, including 6 new preclinical nominations and 8 clinical programs. The Lilly tie-up, where Lilly also holds an investment stake, leverages Insilico's AI capabilities for novel oral therapeutics in high-need areas.

The partnership underscores AI's role in accelerating drug discovery for complex indications, positioning Insilico to monetize its technology while Lilly bolsters its portfolio with potentially best-in-class candidates amid competition in metabolic diseases. Insilico's lead internal asset, rentosertib for idiopathic pulmonary fibrosis, progresses to phase 3 trials, diversifying beyond partnerships.